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Summary
Objective: To determine whether glucosamine-3-sulfate, glucose-3-sulfate (control) and N-acetyl glucosamine inhibit experimentally induced
degradation of equine articular cartilage explants similar to glucosamine HCl.
Design: Articular cartilage was obtained from the antebrachio-carpal and middle joints of horses (2–8 years old) killed for reasons unrelated
to lameness. Cartilage discs were harvested from the weight-bearing region of the articular surface and cultured. Media were exchanged
daily and the recovered media stored at 4°C. On days 1 and 2 lipopolysaccharide (LPS, 10 g/ml) was added to induce cartilage
degradation. To evaluate the effects of different sources of glucosamine (on an equal molar basis), varying concentrations of glucosamine
HCl (0.25, 2.5, or 25 mg/ml), glucosamine-3-sulfate (0.304, 3.04, or 30.4 mg/ml), or N-acetyl-glucosamine (0.256, 2.56, or 25.6 mg/ml) were
added to the cultures. The glucose-3-sulfate control was added at 0.3075, 3.075 or 30.75 mg/ml. Nitric oxide and proteoglycan released into
conditioned media and tissue proteoglycan synthesis and total tissue PG content were measured as indicators of cartilage metabolism.
Results: Glucosamine-3-sulfate consistently inhibited cartilage degradation in a manner similar to glucosamine HCl, while the effects of
N-acetyl-glucosamine were highly variable and did not inhibit cartilage degradation. Glucose-3-sulfate did not inhibit cartilage degradation.
Conclusion: Our results indicate that glucosamine sulfate also has the potential to prevent or reduce articular cartilage degradation similar
to glucosamine HCl in vitro. The amine group at the carbon-2 position appears important for the effectiveness of the glucosamine derivative.
The therapeutic value of N-acetyl-glucosamine remains questionable. © 2000 OsteoArthritis Research Society International
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Osteoarthritis (OA), characterized by the progressive
degradation of articular cartilage, is a debilitating lower
extremity disease in both humans and animals. Degra-
dation of cartilage in joints can cause joint inflammation,
pain, decreased mobility, and reduce performance of
athletic humans, horses and dogs. Once clinical signs of
OA are detectable, the disease is considered irreversible.
Therefore, medical attention has turned to means of pre-
venting OA, treating symptoms and slowing the progression
of the disease. Traditional treatments including surgery,
non-steroidal antiinflammatory drugs, or corticosteroids
have had limited success and are often accompanied by
significant side-effects preventing long-term use. The
medical/veterinary community has thus been forced to ex-
plore non-traditional treatments of this disease, including
many nutritional supplements purported to ameliorate the
symptoms of OA.
Recently, glucosamine has become a popular nutritional
supplement for the treatment of OA in humans. It is a
naturally occurring, non-toxic compound that, when given
orally, has been shown to decrease pain and improve444mobility in osteoarthritic joints of humans.1–5 In horses
suffering from clinical signs of OA, an orally administered
glucosamine HCl-chondroitin sulfate compound appeared
to alleviate OA symptoms.6 Similar findings have been
observed in dogs treated with an oral glucosamine HCl-
chondroitin sulfate supplement.7 Most recently, our labora-
tory has shown that glucosamine HCl can prevent equine
articular cartilage degradation in vitro.8
Glucosamine is commercially available in one of three
forms: glucosamine HCl; glucosamine sulfate; and
N-acetyl-D-glucosamine. Very little information is available
on the pharmacokinetics and bioavailability of the different
forms. One manufacturer claims the HCl and sulfate forms
both dissolve in the stomach and are readily absorbed in
the small intestine. Setnikar et al.9 administered radioactive
glucosamine sulfate to dogs and followed its distribution; it
diffused rapidly from the blood stream into the body and
was actively taken up by the liver, kidney and articular
cartilage. In humans, the pharmacokinetics of glucosamine
sulfate are similar to those of dogs and rats.1,10 Therefore,
oral dosing with glucosamine seems an appropriate
method of therapeutic administration.
The majority of clinical studies on oral glucosamine
supplementation have been performed with glucosamine
sulfate in humans1,11,12 and glucosamine HCl in animals
(horse and dog primarily). Both sources elicit favorable
responses and lack significant side-effects; however, long-
term use has not been evaluated.1,12 Glucosamine HCl is
even being included in sporting dog food for ‘good jointResearch supported by the Michigan Animal Industry Coalition
and the Michigan Agriculture Experiment Station.
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All chemicals were purchased from Sigma (St. Louis,
MO, U.S.A.) unless otherwise noted. Glucosamine and the
derivatives used in this study all had a minimum purity of
99% and the structures were confirmed by Sigma chemical
analysis.degradation and the glucose control did not.EXPLANT CULTURES
Articular cartilage was obtained from the antebrachio–
carpal and middle carpal joints of horses (2–8 years old)
killed for reasons other than joint problems. Cartilage discs
(3.5 mm) were biopsied from the weight-bearing region of
the articular surface and did not include calcified cartilage.
Randomly selected explant discs (three per well, 40–60 mg
total) were cultured in a 24-well Falcon culture plate (Fisher
Scientific; Pittsburgh, PA, U.S.A.) with a modified version of
Dulbecco’s modified Eagle’s medium: nutrient mixture F-12
(Ham) (1:1) (Gibco; Grand Island, NY, U.S.A.).13 The media
was supplemented with 10% fetal bovine serum (FBS,
Gibco), 50 g/ml ascorbate and 100 units/ml penicillin/
streptomycin (Gibco). The explants were maintained in
culture in a humidified incubator with 7% CO2 at 37°C.
Explants were maintained in media without serum for
2 days prior to the first of four treatment days. Conditioned
media were removed and replaced daily and stored at 4°C
until analysed for indicators of degradation. Lipopolysac-
charide (LPS) was added (10 g/ml) to induce cartilage
degradation. The effect of glucosamine-3-sulfate and
N-acetyl-D-glucosamine on LPS-induced cartilage degra-
dation compared to glucosamine HCl was evaluated. Vary-
ing concentrations of glucosamine HCl, [0.25 (1.16 mM),
2.5 (11.6 mM), or 25 mg/ml (116.0 mM)], glucosamine-3-
sulfate (0.3075, 3.075 or 30.75 mg/ml; equimolar basis to
glucosamine) and N-acetyl-D-glucosamine (0.256, 2.56 or
25.6 mg/ml; equimolar basis to glucosamine) were added
to the cultures. In a concurrently published study we
showed that a glucose control did not inhibit cartilage
degradation. In this study, glucose-3-sulfate (0.327, 3.27 or
32.7 mg/ml) was tested as a control for the glucose moiety
of glucosamine-3-sulfate and to evaluate the importance of
the amine group on glucosamine. Treatments were per-
formed with triplicate wells using tissue from one animal
donor. Experiments were repeated at least three times,
each time using tissue from a different animal donor. Tissue
wet weight was determined by individually weighing the
tissue from each well. Tissue was tapped dry, placed in apre-weighed vial and weighed immediately using an
analytical balance.PROTEOGLYCAN ASSAY
Proteoglycan (PG) release into conditioned media was
measured using a dimethylmethylene blue assay as pre-
viously described.14 Briefly, PG content was determined by
measuring sulfated glycosaminoglycan content compared
to a chondroitin sulfate standard and expressed as g
PG/well. Tissue PG content was determined following
papain digest (1 g papain/mg tissue) of the tissue. Tissue
PG content was expressed as g PG/mg tissue wet weight.NITRIC OXIDE ASSAY
Nitrite, a stable end product of nitric oxide (NO) metab-
olism, was measured in conditioned media using the Greiss
reaction and sodium nitrite as a standard.15 Absorbance at
540 nm was determined using the SpectraMax 300 plate
reader (Molecular Devices, Sunnyvale, CA, U.S.A.).QUANTIFICATION OF PROTEOGLYCAN SYNTHESIS
PG synthesis was quantified by measuring the incorpor-
ation of radioactive sulfur into PGs. Media containing
treatments and 25 Ci of [35S]-sulfate/ml (ICN, Costa
Mesa, CA, U.S.A.) were added to explants and cultured for
24 h. PGs were extracted from explant tissue at 4°C for
72 h with 4 M guanidine hydrochloride including proteinase
inhibitors.16 Proteoglycans were isolated using cetylpyrid-
inium chloride (CPC) precipitation.17,18 Briefly, 100 l of
conditioned media or tissue extract was spotted onto
chromatography paper and incubated with 0.1% CPC and
0.3 M NaCl. Chromatography paper was dried and
assayed for radioactivity, using a liquid scintillation system.
Results were presented as counts per minute per milligram
of cartilage wet weight (cpm/mg).STATISTICAL ANALYSIS
Data for indicators of degradation (NO production and
PG release) were analysed using the repeated measure
option of the SAS statistical software PROC MIXED.19 No
interaction of day was present so all data were represented
as the average response of the three treatment wells at
24 h after treatment addition. Treatments were compared
using the Bonferroni procedure. Synthesis data were nor-
malized by an inverse transformation and analysed using
PROC GLM.19 Treatments were compared using the least
squares difference procedure. Statistical significance was
considered at P<0.05 unless otherwise noted.Results
Preliminary experiments indicated that the maximal
release of NO and PG into the conditioned media was
24 h after the addition of LPS. Therefore all data is
represented as 24 h after treatment. Our laboratory has
shown that glucosamine HCl inhibits LPS-induced cartilage
8health’. N-acetyl-glucosamine is found in many commer-
cially available glucosamine complex supplements but has
not been studied clinically. Most commercially available
supplements contain a combination of the three sources of
glucosamine, even though glucosamine sulfate is the pri-
mary source clinically studied in humans. We used our
recently developed equine cartilage degradation system to
study these compounds in vitro. The objective of this
research was to evaluate the relative effectiveness of the
glucosamine derivatives in preventing cartilage degra-
dation in vitro. We report that glucosamine sulfate consist-
ently inhibited cartilage degradation in a manner similar to
glucosamine HCl, while the effects of N-acetyl-glucosamine
were highly variable and generally did not inhibit cartilage
degradation.
446 J. I. Fenton et al.: Effects of glucosamine derivativesFig. 1. (a) Mean (±S.D.) nitric oxide production released into the conditioned media 24 h after LPS-induced degradation treated with
glucosamine sulfate. (b) Mean (±S.D.) proteoglycan production released into the conditioned media 24 h after LPS-induced degradation
treated with glucosamine sulfate. (c) Mean (±S.D.) tissue proteoglycan synthesis as indicated by cpm/mg tissue (wet weight) 24 h after
LPS-induced degradation treated with glucosamine sulfate. *Indicates statistical significance at P≤0.05 compared to LPS. FBS=fetal bovine
serum; LPS=lipopolysaccharide, SO4=sulfate.EFFECT OF GLUCOSAMINE SULFATE ON LPS-INDUCED CARTILAGE
DEGRADATION
Glucosamine-3-sulfate was added at three doses
(0.3075, 3.075 30.75 mg/ml) to the LPS-induced cartilage
degradative system. When tested against LPS treatment,glucosamine-3-sulfate significantly inhibited NO production
at 3.075 and 30.75 mg/ml [Fig. 1(a)], and also inhibited
PG release at the highest dose [Fig. 1(b)]. Additionally,
glucosamine-3-sulfate (30.75 mg/ml) significantly inhibited
tissue PG synthesis compared to all other treatments [Fig.
1(c)] consistent with glucosamine HCl treatment.8
Osteoarthritis and Cartilage Vol. 8 No. 6 447Fig. 2. (a) Mean (±S.D.) nitric oxide production released into the conditioned media 24 h after LPS-induced degradation treated with
glucose-3-sulfate. (b) Mean (±S.D.) proteoglycan production released into the conditioned media 24 h after LPS-induced degradation treated
with glucose-3-sulfate. (c) Mean (±S.D.) total tissue proteoglycan content per mg tissue (wet weight) 24 h after LPS-induced degradation
treated with glucose-3-sulfate. *Indicates statistical significance at P≤0.05 compared to LPS. FBS=fetal bovine serum;
LPS=lipopolysaccharide.Glucose-3-sulfate, a sugar moiety control, was added at
three doses (0.327, 3.27 and 32.7 mg/ml) to the LPS-
induced degradative system. Glucose-3-sulfate did not
significantly inhibit LPS-induced NO production [Fig. 2(a)]and PG release [Fig. 2(b)] consistent with glucose
treatment.8 At the highest dose of glucose-3-sulfate,
the increase in NO and PG was statistically significant.
Therefore, total tissue PG content was measured after
448 J. I. Fenton et al.: Effects of glucosamine derivativesFig. 3. (a) Mean (±S.D.) nitric oxide production released into the conditioned media 24 h after LPS-induced degradation treated with N-acetyl
glucosamine. (b) Mean (±S.D.) proteoglycan production released into the conditioned media 24 h after LPS-induced degradation treated with
N-acetyl-glucosamine. (c) Mean (±S.D.) total tissue proteoglycan content per mg tissue (wet weight) 24 h after LPS-induced degradation
treated with N-acetyl glucosamine. *Indicates statistical significance at P≤0.05 compared to LPS. FBS=fetal bovine serum;
LPS=lipopolysaccharide.
Osteoarthritis and Cartilage Vol. 8 No. 6 449glucose-3-sulfate treatment to determine if there was a
significant degradation of tissue PGs. At the highest dose of
glucose-3-sulfate there was a trend for decreased PG
content [Fig. 2(c)].EFFECT OF N-ACETYL-GLUCOSAMINE ON LPS INDUCED
CARTILAGE DEGRADATION
N-acetyl-glucosamine was added at three doses (0.256,
2.56 25.6 mg/ml) to the LPS-induced degradative system.
N-acetyl-glucosamine did not inhibit NO production [Fig.
3(a)], or PG release [Fig. 3(b)]. Although not significantly
different, NO and PG release appeared to slightly increase
with dose. Therefore, tissue PG content was determined to
further indicate degradation. Tissue PG content did not
change as a result of N-acetyl-glucosamine treatment
[Fig. 3(c)]. PG synthesis was not determined due to lack
of significant changes in other indicators of cartilage
metabolism.Fig. 4. Diagram of the structure N-acetyl glucosamine, glucosamine-3-sulfate, and glucose-3-sulfate compared to glucosamine and glucose.Discussion
This study is the first to compare the three common
commercially available sources of glucosamine
(glucosamine-3-sulfate, N-acetyl-glucosamine and glu-
cosamine HCl) using an in vitro model for cartilage degra-
dation. In a recently published article, we have shown that
glucosamine HCl inhibits LPS or interleukin-1 induced
cartilage degradation as indicated by decreased PG and
NO release and matrix metalloproteinase (MMP) activity,
while the glucose control did not, and we discussed poten-
tial mechanisms.8 Using that in vitro model we show that
glucosamine-3-sulfate consistently inhibits cartilage degra-
dation in a manner similar to glucosamine HCl, while the
effects of N-acetyl glucosamine were highly variable and
did not inhibit cartilage degradation. The glucose-3-sulfate
control also did not inhibit cartilage degradation.Comparing these five compounds (glucosamine-3-
sulfate, N-acetyl glucosamine, glucosamine HCl, glucose
and glucose-3-sulfate) indicates the importance of the free
amine group related to the bioactivity of glucosamine.
Glucosamine-3-sulfate and glucose-3-sulfate, as well as
glucosamine (HCl) and glucose, differ only by the −NH2
group substitution for the −OH on the second carbon of the
six-carbon backbone (Fig. 4). In both glucosamine-3-
sulfate and glucosamine HCl, the amine group exists in a
free form. However, in nature the amine group does not
exist in this free form: it is usually acetylated or sulfated.
Interestingly, the acetylated form of glucosamine, N-acetyl
glucosamine, did not inhibit cartilage degradation in our
system, suggesting the importance of the reactive amine
group for bioactivity of glucosamine.
Consistent with our findings, Sandy et al.20 recently
showed that glucosamine inhibited aggrecanase-mediated
cleavage of aggrecan (the primary proteoglycan in articular
cartilage) at 10 mM. In addition, GlcNac did not inhibit
aggrecanase-mediated cleavage of aggrecan at 15 mM.20
Mannosamine, a structural isomer of glucosamine with a
free amine group, has been shown to inhibit aggrecanase-
mediated cleavage of aggrecan at one-tenth the concen-
tration of glucosamine.20 Mannosamine and glucosamine
have also recently been shown to inhibit IL-1-induced
changes in the physical properties of bovine calf cartilage
in vitro.21
In a previous paper, we discuss some possible mech-
anisms of action of glucosamine.8 Among these is the
possibility that glucosamine may simply quench small sig-
nal molecules including NO and oxygen radicals that can
damage articular cartilage.22 This explanation seems
plausible, considering the lack of inhibition of cartilage
degradation observed by N-acetyl glucosamine. Glucos-
amine may also mediate matrix metalloproteinase degra-
dation of cartilage, often thought of as the hallmark of OA.
Glucosamine has been shown to inhibit aggrecanase-
mediated (a member of the ADAMTS family) cleavage of
450 J. I. Fenton et al.: Effects of glucosamine derivativesaggrecan in IL-1 stimulated bovine cartilage explants.23
This inhibition was apparently not due to any cytotoxicity or
interference with IL-1 signaling, since protein synthesis and
lactate production were not significantly altered by glu-
cosamine. In agreement with this conclusion, we were not
able to detect any decrease in cell viability as measured by
lactate dehydrogenase (data not shown).
During the diseased state there may be an increased
demand for ‘building blocks’ of cartilage metabolism. Sup-
plemental glucosamine may also simply bypass rate-
limiting steps in glucosamine metabolism and lead to an
increase in available ‘building blocks’ for extracellular
matrix molecules. Addition of glucosamine to cell culture
resulted in an increase in intracellular UDP-N-
acetylglucosamine.24 This compound is critical in the for-
mation of glycosaminoglycans found in cartilage including
hyaluronic acid, heparin sulfate, and keratan sulfate. Sup-
plemental glucosamine may act to reduce symptoms of OA
by increasing the production of hyaluronic acid in synovial
fluid.25 Intraarticular injection of hyaluronic acid has been
shown to alleviate the symptoms of OA.26 HA has also
been shown to prevent fibronectin mediated cartilage injury
in vivo27 and in vitro.28
Our in-vitro data support the reported therapeutic value
of glucosamine sulfate and glucosamine HCl. However, we
do not show any effect of N-acetyl glucosamine on the
prevention of cartilage degradation. Lack of FDA regulation
of compounds classified as nutrients allows for a variety of
sources of glucosamine in nutritional supplements whether
or not they are proven effective or have been tested
clinically. Although investigations of glucosamine HCl and
glucosamine sulfate conducted so far indicate beneficial
effects, the medical community has not embraced this as a
treatment for OA. Many of the studies have serious flaws29
and limited data are available regarding the adverse effects
or potential drug interactions of glucosamine. Further
research to elucidate its mode of action and to evaluate its
long-term efficacy in humans and animals such as horses is
necessary to validate its preventative and therapeutic value
in OA. Several combinations of glucosamine and its deriva-
tives are commercially available. Our research suggests
that their relative effectiveness in improving joint health
could depend on the composition of the supplements, with
glucosamine HCl and glucosamine sulfate being more
important than N-acetylglucosamine.Table I
Detailed description of components of explant culture treatments*
Treatment FBS
(%)
LPS Glucose-
3-sulfate
Glucosamine-
3-sulfate
N-acetyl-
glucosamine
FBS-control 1 10
LPS-control 2 10 10 g/ml
Treatment 1 10 10 g/ml 0.327 mg/ml
Treatment 2 10 10 g/ml 3.27 mg/ml
Treatment 3 10 10 g/ml 32.7 mg/ml
Treatment 4 10 10 g/ml 0.3075 mg/ml
Treatment 5 10 10 g/ml 3.075 mg/ml
Treatment 6 10 10 g/ml 30.75 mg/ml
Treatment 7 10 10 g/ml 0.256 mg/ml
Treatment 8 10 10 g/ml 2.56 mg/ml
Treatment 9 10 10 g/ml 25.6 mg/ml
*FBS=fetal bovine serum; LPS=lipopolysaccharide.References
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